Emerging data suggest this peptide, a dual agonist targeting both the gut-brain axis and GIP , appears to offer a promising step forward for obesity treatment. Preliminary human trials have shown https://getretatrutideaustralia.com/blog/retatrutide-weight-loss-revolution-2026